Vectorite Biomedical Past Earnings Performance
Past criteria checks 0/6
Vectorite Biomedical has been growing earnings at an average annual rate of 41.1%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 8% per year.
Key information
41.1%
Earnings growth rate
51.7%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 8.0% |
| Return on equity | -4.8% |
| Net Margin | -37.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vectorite Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 53 | -20 | 27 | 11 |
| 31 Mar 24 | 55 | -13 | 27 | 9 |
| 31 Dec 23 | 56 | -7 | 26 | 7 |
| 30 Sep 23 | 54 | -8 | 25 | 6 |
| 30 Jun 23 | 53 | -10 | 25 | 6 |
| 31 Mar 23 | 48 | -18 | 25 | 6 |
| 31 Dec 22 | 43 | -26 | 26 | 5 |
| 30 Sep 22 | 38 | -27 | 26 | 6 |
| 30 Jun 22 | 32 | -28 | 25 | 7 |
| 31 Mar 22 | 31 | -10 | 26 | 10 |
| 31 Dec 21 | 29 | 8 | 27 | 13 |
| 30 Sep 21 | 28 | -4 | 30 | 15 |
| 30 Jun 21 | 26 | -17 | 33 | 17 |
| 31 Mar 21 | 25 | -42 | 35 | 22 |
| 31 Dec 20 | 25 | -68 | 37 | 26 |
| 30 Sep 20 | 25 | -76 | 38 | 32 |
| 30 Jun 20 | 25 | -85 | 39 | 39 |
| 31 Mar 20 | 26 | -87 | 40 | 42 |
| 31 Dec 19 | 27 | -90 | 41 | 45 |
| 30 Sep 19 | 53 | -66 | 61 | 43 |
| 30 Jun 19 | 79 | -42 | 82 | 41 |
| 31 Mar 19 | 143 | -36 | 138 | 37 |
| 31 Dec 18 | 206 | -30 | 193 | 34 |
| 30 Sep 18 | 238 | -42 | 222 | 35 |
| 30 Jun 18 | 270 | -53 | 251 | 36 |
| 31 Mar 18 | 207 | -58 | 195 | 33 |
| 31 Dec 17 | 144 | -63 | 139 | 30 |
| 30 Sep 17 | 87 | -71 | 93 | 25 |
| 30 Jun 17 | 29 | -80 | 47 | 20 |
| 31 Mar 17 | 32 | -80 | 56 | 20 |
| 31 Dec 16 | 35 | -80 | 66 | 20 |
| 30 Sep 16 | 35 | -80 | 69 | 19 |
| 30 Jun 16 | 34 | -81 | 72 | 19 |
| 31 Mar 16 | 32 | -77 | 72 | 18 |
| 31 Dec 15 | 30 | -73 | 72 | 17 |
| 30 Sep 15 | 64 | -18 | 84 | 17 |
| 30 Jun 15 | 98 | 37 | 96 | 16 |
| 31 Mar 15 | 95 | 34 | 93 | 16 |
| 31 Dec 14 | 93 | 31 | 91 | 15 |
| 30 Sep 14 | 65 | -8 | 78 | 15 |
| 30 Jun 14 | 37 | -46 | 65 | 14 |
| 31 Mar 14 | 39 | -37 | 65 | 14 |
| 31 Dec 13 | 41 | -28 | 65 | 13 |
Quality Earnings: 4170 is currently unprofitable.
Growing Profit Margin: 4170 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4170 is unprofitable, but has reduced losses over the past 5 years at a rate of 41.1% per year.
Accelerating Growth: Unable to compare 4170's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4170 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).
Return on Equity
High ROE: 4170 has a negative Return on Equity (-4.85%), as it is currently unprofitable.